| |
P
|
Deferiprone group (n = 39)
|
Combined group (n = 51)
|
Deferoxamine group (n = 74)
|
P
|
|---|
|
Age (yrs)
|
0.136
|
31.5 ± 5.3
|
29.6 ± 6.5
|
32.7 ± 8.5
|
0.032
|
|
Male (%)
|
0.022
|
69.2%
|
45.1%
|
48.6%
|
0.719
|
|
Chel. starting age (yrs)
|
0.499
|
5.1 ± 5.1
|
4.3 ± 4.1
|
6.6 ± 4.9
|
0.030
|
|
Pre-transfusion Hb (g/dl)
|
0.379
|
9.5 ± 0.7
|
9.6 ± 0.5
|
9.7 ± 0.6
|
0.213
|
|
Ferritin (ng/l)
|
0.001
|
941 ± 1541
|
1814 ± 1033
|
1093 ± 1256
|
0.001
|
|
Global Heart (ms)
|
0.0001
|
31.3 ± 11.3
|
21.5 ± 12.9
|
28.5 ± 10.7
|
0.002
|
|
MRI CIC
(mg/g dry w)
|
0.001
|
0.94 ± 0.79
|
2.15 ± 2.38
|
1.03 ± 0.79
|
0.001
|
|
N seg. with T2* < 20 ms
|
0.001
|
3.9 ± 6.2
|
8.7± 7.0
|
4.4 ± 5.9
|
0.001
|
|
Mid septum T2* (ms)
|
0.0001
|
34.0 ± 13.0
|
22.3 ± 14.3
|
30.6 ± 12.8
|
0.001
|
|
LV EF (%)
|
0.643
|
61.8 ± 9.0
|
62.6 ± 7.0
|
61.6 ± 6.0
|
0.364
|
|
LV EDVI (ml/m2)
|
0.069
|
91.9 ± 20.0
|
84.7 ± 17.6
|
89.6 ± 20.2
|
0.164
|
|
RV EF (%)
|
0.336
|
59.9 ± 8.8
|
61.6 ± 6.8
|
60.9 ± 7.0
|
0.587
|
|
RV EDVI (ml/m2)
|
0.126
|
89.7 ± 19.9
|
83.8 ± 16.4
|
88.1 ± 20.5
|
0.210
|
|
Liver T2* (ms)
|
0.110
|
8.9 ± 8.0
|
6.3 ± 6.8
|
11.0 ± 7.5
|
0.0001
|
|
MRI LIC
(mg/g dry weight)
|
0.330
|
8.2 ± 8.9
|
10.3 ± 10.1
|
5.3 ± 6.2
|
0.003
|
- All values are quoted as mean ± SD. The P-values concern the comparison between combined and deferiprone groups and between combined and deferoxamine groups.
